{
    "id": 3749,
    "fullName": "HRAS G12R",
    "impact": "missense",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "HRAS G12R is hotspot mutation that lies within the GTP binding domain of the Hras protein (UniProt.org). G12R results in decreased Hras GTPase activity and leads to transformation of cells in culture (PMID: 3042780, PMID: 6092966).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 2098,
                    "pubMedId": 6092966,
                    "title": "Biological properties of human c-Ha-ras1 genes mutated at codon 12.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/6092966"
                },
                {
                    "id": 12367,
                    "pubMedId": 3042780,
                    "title": "Biochemical properties of Ha-ras encoded p21 mutants and mechanism of the autophosphorylation reaction.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/3042780"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 3265,
        "geneSymbol": "HRAS",
        "terms": [
            "HRAS",
            "C-BAS/HAS",
            "C-H-RAS",
            "C-HA-RAS1",
            "CTLO",
            "H-RASIDX",
            "HAMSV",
            "HRAS1",
            "p21ras",
            "RASH1"
        ]
    },
    "variant": "G12R",
    "createDate": "03/14/2015",
    "updateDate": "10/04/2018",
    "referenceTranscriptCoordinates": {
        "id": 132116,
        "transcript": "NM_001130442",
        "gDna": "chr11:g.534289C>G",
        "cDna": "c.34G>C",
        "protein": "p.G12R",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 7864,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sprycel (dasatinib) and Mekinist (trametinib) synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R and HRAS G12R in culture (PMID: 27222538).",
            "molecularProfile": {
                "id": 26080,
                "profileName": "HRAS G12R KRAS G13R"
            },
            "therapy": {
                "id": 4599,
                "therapyName": "Dasatinib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1781,
                "name": "thyroid gland cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6508,
                    "pubMedId": 27222538,
                    "title": "The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27222538"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7865,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sprycel (dasatinib) and Selumetinib (AZD6244) synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R and HRAS G12R in culture (PMID: 27222538).",
            "molecularProfile": {
                "id": 26080,
                "profileName": "HRAS G12R KRAS G13R"
            },
            "therapy": {
                "id": 4600,
                "therapyName": "Dasatinib + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1781,
                "name": "thyroid gland cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6508,
                    "pubMedId": 27222538,
                    "title": "The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27222538"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7854,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited growth of thyroid cancer cell lines harboring KRAS G13R and HRAS G12R in culture and in cell line xenograft models (PMID: 27222538).",
            "molecularProfile": {
                "id": 26080,
                "profileName": "HRAS G12R KRAS G13R"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1781,
                "name": "thyroid gland cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6508,
                    "pubMedId": 27222538,
                    "title": "The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27222538"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7866,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sprycel (dasatinib) and SCH772984 synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R and HRAS G12R in culture (PMID: 27222538).",
            "molecularProfile": {
                "id": 26080,
                "profileName": "HRAS G12R KRAS G13R"
            },
            "therapy": {
                "id": 4601,
                "therapyName": "Dasatinib + SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1781,
                "name": "thyroid gland cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6508,
                    "pubMedId": 27222538,
                    "title": "The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27222538"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7858,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) inhibited growth of thyroid cancer cell lines harboring KRAS G13R and HRAS G12R in culture (PMID: 27222538).",
            "molecularProfile": {
                "id": 26080,
                "profileName": "HRAS G12R KRAS G13R"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1781,
                "name": "thyroid gland cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6508,
                    "pubMedId": 27222538,
                    "title": "The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27222538"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 3555,
            "profileName": "HRAS G12R",
            "profileTreatmentApproaches": [
                {
                    "id": 1613,
                    "name": "MEK1 Inhibitor",
                    "profileName": "HRAS G12R"
                },
                {
                    "id": 1620,
                    "name": "RAS Inhibitor (Pan)",
                    "profileName": "HRAS G12R"
                },
                {
                    "id": 1617,
                    "name": "PIK3CB inhibitor",
                    "profileName": "HRAS G12R"
                },
                {
                    "id": 1615,
                    "name": "PI3K Inhibitor (Pan)",
                    "profileName": "HRAS G12R"
                },
                {
                    "id": 1612,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "HRAS G12R"
                },
                {
                    "id": 1614,
                    "name": "MEK2 Inhibitor",
                    "profileName": "HRAS G12R"
                },
                {
                    "id": 1616,
                    "name": "PIK3CA inhibitor",
                    "profileName": "HRAS G12R"
                },
                {
                    "id": 1619,
                    "name": "PIK3CG inhibitor",
                    "profileName": "HRAS G12R"
                },
                {
                    "id": 1618,
                    "name": "PIK3CD inhibitor",
                    "profileName": "HRAS G12R"
                }
            ]
        },
        {
            "id": 26080,
            "profileName": "HRAS G12R KRAS G13R",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 132115,
            "transcript": "NM_005343",
            "gDna": "chr11:g.534289C>G",
            "cDna": "c.34G>C",
            "protein": "p.G12R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 132117,
            "transcript": "NM_176795",
            "gDna": "chr11:g.534289C>G",
            "cDna": "c.34G>C",
            "protein": "p.G12R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 132116,
            "transcript": "NM_001130442",
            "gDna": "chr11:g.534289C>G",
            "cDna": "c.34G>C",
            "protein": "p.G12R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}